Marillion Pharmaceuticals is a clinical-stage pharmaceuticals company focused on the development and commercialization of novel therapeutics for the treatment of cancers and for supportive care in oncology. Marillion’s product pipeline includes Lu-AMBA, Pilobuc™ and MN-201. Lu-AMBA is a first-in-class receptor targeted therapeutic agent for the treatment of hormone resistant prostate cancer, advanced metastatic breast cancers and non-small cell lung cancers. Lu-AMBA is able to deliver a proprietary compound that targets and binds to specific receptors found on certain cancer cells, thereby allowing a potent radioactive drug to be internalized into the tumor cells. Subsequently, the tumor is irradiated from within, increasing the therapeutic efficacy while helping to protect critical organs. Lu-AMBA can also be used to image cancerous tissue in order to help select patients and adjust the dose used for personalized medicine. Early clinical proof of concept for Lu-AMBA has been demonstrated in advanced hormone resistant prostate cancer patients in a phase I clinical trial initiated in Europe. An IND for a phase I/II clinical trial in the USA is expected to be filed in 2009. Pilobuc™ is a novel, proprietary, buccal insert of the approved muscarinic agonist, pilocarpine, for the use of Xerostomia, a debilitating loss of salivary gland function associated with radiotherapy for head and neck cancers and various autoimmune disorders including Sjögren’s syndrome. Pilobuc™ has completed phase I and phase II clinical trials in Europe and is expected to enter phase II/III clinical trials in the USA in 2009. MN-201 is expected to be the first synthetic vitamin D5 receptor ligand to be advanced into clinical development for a variety of cancers. An IND was approved for a phase I clinical trial of MN-201 in the USA in 2008. |
MARILLION NEWS Marillion Pharmaceuticals Initiates Clinical Development of Novel Anti-Cancer Drug Read More Marillion Pharmaceuticals and Cytokine PharmaSciences Announce License Agreement for Xerostomia Treatment Read More Marillion Pharmaceuticals and Bracco Imaging S.p.A. Announce License Agreement to Develop and Commercialize Novel Cancer Treatment Read More Marillion Parmaceuticals Inc. |
